Anthem Biosciences Ltd - 544449 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Anthem Biosciences has published the audio recording of its Q1 FY27 earnings call. The recording, covering standalone and consolidated financial results for the quarter ended June 30, 2026, is now accessible on the company's website.
Jul 22 2026 18:07:41
Anthem Biosciences Ltd - 544449 - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
Anthem Biosciences reported Q1 FY27 consolidated revenue of Rs.4,182 million, a 22.6% year-on-year decline. Net profit for the quarter fell 11.7% YoY to Rs.1,199 million, indicating a significant downturn in performance.
Jul 21 2026 19:25:08
Anthem Biosciences Ltd - 544449 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Anthem Biosciences reported its Q1 FY27 consolidated financial results. Revenue from operations declined 22.6% YoY to Rs.418.2 crore, and net profit was down 11.7% YoY to Rs.119.9 crore. The company cited timing shifts in deliveries to key customers as the reason for the decline.
Jul 21 2026 16:54:40
Anthem Biosciences Ltd - 544449 - Board Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday, July 21, 2026
Anthem Biosciences board approved Q1 FY27 financial results on July 21, 2026. Cons. revenue stood at ₹418.22 crore (down 22.6% YoY) and net profit at ₹119.94 crore (down 11.7% YoY). Standalone profit for the period was ₹102.01 crore.
Jul 21 2026 16:36:43
Anthem Biosciences Ltd - 544449 - Board Meeting Intimation for Financial Results For Quarter Ended June 30, 2026
Anthem Biosciences' Board of Directors will convene on July 21, 2026, to approve Q1 FY27 standalone and consolidated financial results. This meeting will finalize the company's financial performance for the quarter ending June 30, 2026.
Jul 14 2026 19:02:25
Read More